This is a preview of subscription content, log in via an institution to check access.
Reference
REIFSNIDER O, et al. Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. 80th Annual Scientific Sessions of the American Diabetes Association : abstr. 1158-P, 12 Jun 2020. Available from: URL: https://plan.core-apps.com/tristar_ada20/abstract/2dfd4501-2ada-4b28-af48-652e53e9e2cd
Rights and permissions
About this article
Cite this article
Empagliflozin 2nd-line therapy in T2DM: better outcomes, lower cost in US. PharmacoEcon Outcomes News 858, 15 (2020). https://doi.org/10.1007/s40274-020-6988-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6988-x